Seres Therapeutics, Inc. Form 4

FORM 4

July 01, 2015

OMB APPROVAL

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB 3235-0287 Number:

Check this box if no longer subject to Section 16.

January 31, Expires: STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF

2005 Estimated average burden hours per response... 0.5

Form 4 or Form 5 obligations

may continue.

See Instruction

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section

SECURITIES

30(h) of the Investment Company Act of 1940

2. Issuer Name and Ticker or Trading

Seres Therapeutics, Inc. [MCRB]

1(b).

(Print or Type Responses)

1. Name and Address of Reporting Person * Nestle Health Science US Holdings, Inc.

> (Last) (First) (Middle)

> > (Street)

(State)

(Zip)

C/O NESTLE USA, INC., 383 MAIN AVE., 5TH FLOOR

4. If Amendment, Date Original

3. Date of Earliest Transaction

(Month/Day/Year)

07/01/2015

Symbol

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

Director 10% Owner Other (specify Officer (give title below)

6. Individual or Joint/Group Filing(Check Filed(Month/Day/Year)

Applicable Line) Form filed by One Reporting Person _X_ Form filed by More than One Reporting

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

NORWALK, CT 06851

1.Title of 2. Transaction Date 2A. Deemed 7. Nature of 3. 4. Securities Acquired (A) 5. Amount of Security (Month/Day/Year) Execution Date, if Transaction Disposed of (D) Securities Ownership Indirect (Instr. 3) Code (Instr. 3, 4 and 5) Beneficially Form: Beneficial any (Month/Day/Year) (Instr. 8) Owned Direct (D) Ownership or Indirect Following (Instr. 4) Reported (I) (A) Transaction(s) (Instr. 4)

or (Instr. 3 and 4) (D) Price

Amount

Common

(City)

See Stock, 07/01/2015 Footnote Α 1,333,333 A \$ 18 6,888,888 Ι \$0.001 par (1)

Code V

value

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of SEC 1474 information contained in this form are not (9-02)required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Seres Therapeutics, Inc. - Form 4

	2.	3. Transaction Date		4.	5.	6. Date Exerc		7. Titl		8. Price of	9. Nu
Derivative Security (Instr. 3)	Conversion or Exercise Price of Derivative Security	(Month/Day/Year)	Execution Date, if any (Month/Day/Year)	Transact Code (Instr. 8)	orNumber of Derivativ Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	:		Amou Under Securi (Instr.	lying	Derivative Security (Instr. 5)	Deriv Secur Bene Own Follo Repo Trans (Instr
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

Reporting Owners

Reporting Owner Name / Address	Relationships						
reporting 6 mass runner, runners	Director	10% Owner	Officer	Other			
Nestle Health Science US Holdings, Inc. C/O NESTLE USA, INC. 383 MAIN AVE., 5TH FLOOR NORWALK, CT 06851		X					
NESTLE SA AVE NESTLE 55, CH-1800 VEVEY, V8		X					
NIMCO US, Inc. 383 MAIN AVE., 5TH FLOOR NORWALK CT 06851		X					

Signatures

NESTLE HEALTH SCIENCE US HOLDINGS, INC., By: /s/ James Pepin, Name: James					
Pepin, Title: President					
**Signature of Reporting Person	Date				
NIMCO US, INC., By: /s/ Yun Au, Name: Yun Au, Title: Chief Legal Officer					
**Signature of Reporting Person	Date				
NESTLE S.A., By: /s/ David P. Frick, Name: David P. Frick, Title: Secretary to the Board of					
Directors	07/01/2015				
**Signature of Reporting Person	Date				

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Held by Nestle Health Science US Holdings, Inc. Nestle Health Science US Holdings, Inc. is a wholly owned subsidiary of NIMCO US, Inc., which is a wholly ownd subsidiary of Nestle S.A., a publically traded company. Each of these entities may be deemed to share

Reporting Owners 2

Edgar Filing: Seres Therapeutics, Inc. - Form 4

voting and investment power with respect to all shares held by Nestle Health Science US Holdings, Inc. Each of the filing entities disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.